PubMed

Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura.

Arnold DM, Dentali F, Crowther MA, Meyer RM, Cook RJ, Sigouin C, Fraser GA, Lim W, Kelton JG.

Ann Intern Med. 2007 Jan 2;146(1):25-33. Review.PMID: 17200219 [PubMed - indexed for MEDLINE]Related articlesFree article

Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura.

Braendstrup P, Bjerrum OW, Nielsen OJ, Jensen BA, Clausen NT, Hansen PB, Andersen I, Schmidt K, Andersen TM, Peterslund NA, Birgens HS, Plesner T, Pedersen BB, Hasselbalch HC.

Am J Hematol. 2005 Apr;78(4):275-80.PMID: 15795920 [PubMed - indexed for MEDLINE]Related articles

Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura.

Stasi R, Pagano A, Stipa E, Amadori S.

Blood. 2001 Aug 15;98(4):952-7.PMID: 11493438 [PubMed - indexed for MEDLINE]Related articlesFree article

Management of adult patients with persistent idiopathic thrombocytopenic purpura following splenectomy: a systematic review.

Vesely SK, Perdue JJ, Rizvi MA, Terrell DR, George JN.

Ann Intern Med. 2004 Jan 20;140(2):112-20. Review.PMID: 14734334 [PubMed - indexed for MEDLINE]Related articlesFree article

[Rituximab treatment for adults with steroid-resistant idiopathic thrombocytopenic purpura]

Wang W, Yu QH, Zhang HY, Chu XX, Chen F, Zhang CQ, Zhou YH, Hou M.

Zhonghua Nei Ke Za Zhi. 2008 Mar;47(3):225-7. Chinese. PMID: 18785508 [PubMed - indexed for MEDLINE]Related articles

The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura.

Cooper N, Stasi R, Cunningham-Rundles S, Feuerstein MA, Leonard JP, Amadori S, Bussel JB.

Br J Haematol. 2004 Apr;125(2):232-9.PMID: 15059147 [PubMed - indexed for MEDLINE]Related articles

Rituximab for the treatment of refractory idiopathic thrombocytopenic purpura (ITP) and thrombotic thrombocytopenic purpura (TTP): report of three cases.

Koulova L, Alexandrescu D, Dutcher JP, O'Boyle KP, Eapen S, Wiernik PH.

Am J Hematol. 2005 Jan;78(1):49-54.PMID: 15609292 [PubMed - indexed for MEDLINE]Related articles

Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study.

Godeau B, Porcher R, Fain O, Lefrère F, Fenaux P, Cheze S, Vekhoff A, Chauveheid MP, Stirnemann J, Galicier L, Bourgeois E, Haiat S, Varet B, Leporrier M, Papo T, Khellaf M, Michel M, Bierling P.

Blood. 2008 Aug 15;112(4):999-1004. Epub 2008 May 7.PMID: 18463354 [PubMed - indexed for MEDLINE]Related articlesFree article

Rituximab treatment for chronic refractory idiopathic thrombocytopenic purpura.

Zhou Z, Yang R.

Crit Rev Oncol Hematol. 2008 Jan;65(1):21-31. Epub 2007 Jul 30. Review.PMID: 17681784 [PubMed - indexed for MEDLINE]Related articles

Rituximab treatment for symptomatic chronic ITP.

Tamminga RY, Bruin MC.

Pediatr Blood Cancer. 2006 Oct 15;47(5 Suppl):714-6. Review.PMID: 16933264 [PubMed - indexed for MEDLINE]Related articles

Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura.

Bennett CM, Rogers ZR, Kinnamon DD, Bussel JB, Mahoney DH, Abshire TC, Sawaf H, Moore TB, Loh ML, Glader BE, McCarthy MC, Mueller BU, Olson TA, Lorenzana AN, Mentzer WC, Buchanan GR, Feldman HA, Neufeld EJ.

Blood. 2006 Apr 1;107(7):2639-42. Epub 2005 Dec 13.PMID: 16352811 [PubMed - indexed for MEDLINE]Related articlesFree article

First-line therapies for immune thrombocytopenic purpura: re-evaluating the need to treat.

Rodeghiero F.

Eur J Haematol Suppl. 2008 Feb;(69):19-26. Review.PMID: 18211569 [PubMed - indexed for MEDLINE]Related articles

Rituximab in the management of chronic immune thrombocytopenic purpura: an effective and safe therapeutic alternative in refractory patients.

Peñalver FJ, Jiménez-Yuste V, Almagro M, Alvarez-Larrán A, Rodríguez L, Casado M, Gallur L, Giraldo P, Hernández R, Menor D, Rodríguez MJ, Caballero D, González R, Mayans J, Millán I, Cabrera JR; Multi-institutional Retrospective Spanish Study Group on the Use of Rituximab in Refractory ITP.

Ann Hematol. 2006 Jun;85(6):400-6. Epub 2006 Mar 21. Erratum in: Ann Hematol. 2006 Aug;85(8):558. Dosage error in article text. PMID: 16550390 [PubMed - indexed for MEDLINE]Related articles

Rituximab for immune cytopenia in adults: idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, and Evans syndrome.

Shanafelt TD, Madueme HL, Wolf RC, Tefferi A.

Mayo Clin Proc. 2003 Nov;78(11):1340-6.PMID: 14601692 [PubMed - indexed for MEDLINE]Related articlesFree article

Rituximab in the treatment of idiopathic thrombocytopenic purpura (ITP).

Alasfoor K, Alrasheed M, Alsayegh F, Mousa SA.

Ann Hematol. 2009 Mar;88(3):239-43. Epub 2008 Aug 15.PMID: 18704420 [PubMed - indexed for MEDLINE]Related articles

Low rate of long-lasting remissions after successful treatment of immune thrombocytopenic purpura with rituximab.

Schweizer C, Reu FJ, Ho AD, Hensel M.

Ann Hematol. 2007 Oct;86(10):711-7. Epub 2007 Jul 11.PMID: 17622529 [PubMed - indexed for MEDLINE]Related articles

Should rituximab be used before or after splenectomy in patients with immune thrombocytopenic purpura?

Cooper N, Evangelista ML, Amadori S, Stasi R.

Curr Opin Hematol. 2007 Nov;14(6):642-6. Review.PMID: 17898569 [PubMed - indexed for MEDLINE]Related articles

Rituximab (anti-CD20 monoclonal antibody) in children with chronic refractory symptomatic immune thrombocytopenic purpura: efficacy and safety of treatment.

Parodi E, Nobili B, Perrotta S, Rosaria Matarese SM, Russo G, Licciardello M, Zecca M, Locatelli F, Cesaro S, Bisogno G, Giordano P, De Mattia D, Ramenghia U.

Int J Hematol. 2006 Jul;84(1):48-53.PMID: 16867902 [PubMed - indexed for MEDLINE]Related articles

Chronic refractory idiopathic thrombocytopenic purpura (ITP) and anti-CD20 monoclonal antibody: a case report.

Latifzadeh SZ, Entezari V.

Clin Appl Thromb Hemost. 2006 Oct;12(4):489-92.PMID: 17000895 [PubMed - indexed for MEDLINE]Related articles

Treatment of relapsed idiopathic thrombocytopenic purpura with the anti-CD20 monoclonal antibody rituximab: a pilot study.

Giagounidis AA, Anhuf J, Schneider P, Germing U, Söhngen D, Quabeck K, Aul C.

Eur J Haematol. 2002 Aug;69(2):95-100.PMID: 12366712 [PubMed - indexed for MEDLINE]Related articles